Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Ursodeoxycholic acid (UDCA) has been proposed as beneficial therapy for patients with primary biliary cirrhosis (PBC). The effects of UDCA on metabolic bone disease, a major source of morbidity in patients with PBC, are essentially unknown. Preliminary information suggests that UDCA may improve biochemical indices of bone disease, although information about the effects of bone disease, although information about the effects of UDCA on bone density is lacking. In this study, we describe the effects of UDCA on lumbar spine bone mineral densities over a 3-year period during which patients were enrolled in a randomized, double-blind, therapeutic trial of UDCA for the treatment of PBC. Lumbar spine dual-photon densitometry was measured at entry and annually. Eighty-eight patients, 50 in the UDCA group and 38 in the placebo group, had serial measurements available for up to 3 years. There was no statistical difference between the two treatment groups at entry with respect to histologist stage, total bilirubin, age, use of calcium supplement, vitamin D levels, or estrogen. After 3 years of treatment, there was no significant difference in the lumbar spine bone desnitometry measurements between the UDCA-treated and placebo groups. We conclude that, after 3 years of treatment, UDCA is not associated with statistically significant differences in the rate of bone loss from the lumbar spine in patients when compared with placebo despite beneficial effects of treatment on the underlying liver disease. Further efforts to define effective treatments for the bone disease need to be pursued. (Hepatology 1995;21:389-392.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationEastell, R., Dickson, R. E., Hodgson, S. F., Wiesner, R. H., Porayko, M. K., Wahner, H. W., Cedel, S. L., Riggs, L. B., & Krom, R. A. F. (1991) · Hepatology · doi:10.1002/hep.1840140215 · Cited by 297
Self-citationPrevalence and prediction of osteopenia in chronic liver disease
Bonkovsky, H. L., Hawkins, M., Steinberg, K., Hersh, T., Galambos, J. T., Henderson, M. J., Millikan, W. J., & Galloway, J. R. (1990) · Hepatology · doi:10.1002/hep.1840120214 · Cited by 133
Cited by
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationACG clinical guideline: primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.112 · Cited by 524
Self-citationKaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Management of primary biliary cirrhosis
Heathcote, J. E. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 417
Hirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
Guidelines on the management of osteoporosis associated with chronic liver disease
Collier, J. D., Ninkovic, M., & Compston, J. E. (2002) · Gut · doi:10.1136/gut.50.suppl_1.i1 · Cited by 241
Bone disorders in chronic liver disease
Collier, J. (2007) · Hepatology · doi:10.1002/hep.21852 · Cited by 238
Crucial Role of Vitamin D in the Musculoskeletal System
Wintermeyer, E., Ihle, C., Ehnert, S., Stöckle, U., Ochs, G., De Zwart, P., Flesch, I., Bahrs, C., & Nussler, A. (2016) · Nutrients · doi:10.3390/nu8060319 · Cited by 216
“, 1995 [102] 88 primary biliary cirrhosis n.”
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
Menon, K. V. N., Angulo, P., Weston, S., Dickson, E. R., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00144-1 · Cited by 180
Self-citationGuañabens, N., Parés, A., Ros, I., Caballería, L., Pons, F., Vidal, S., Monegal, A., Peris, P., & Rodés, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.035 · Cited by 179
Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142
Self-citationRouillard, S., & Lane, N. E. (2001) · Hepatology · doi:10.1053/jhep.2001.20533 · Cited by 125
Current understanding of osteoporosis associated with liver disease
Nakchbandi, I. A., & van der Merwe, S. W. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.166 · Cited by 98
Osteoporosis in liver diseases and after liver transplantation
Hay, J. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00143-0 · Cited by 72
Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment
Parés, A., & Guañabens, N. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.005 · Cited by 63
Levy, C., Harnois, D. M., Angulo, P., Jorgensen, R., & Lindor, K. D. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01026.x · Cited by 62
Self-citationChen, C.-H., Lin, C.-L., & Kao, C.-H. (2015) · Medicine · doi:10.1097/md.0000000000002276 · Cited by 61
Osteoporosis in primary biliary cholangitis
Danford, C. J., Trivedi, H. D., Papamichael, K., Tapper, E. B., & Bonder, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3513 · Cited by 56
Boone, R. H., Cheung, A. M., Girlan, L. M., & Heathcote, E. J. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-8015-x · Cited by 54
“Ursodeoxycholic acid improves the prognosis in PBC (10, 11), but does not alter the rate of bone loss (12).”
BackgroundTreatment of bone disorders in liver disease
Parés, A., & Guañabens, N. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.007 · Cited by 50
“Overall, approximately 23% of the patientswith liver disease have osteoporosis, with ahigher prevalence in patients with primary biliary cirrhosis (about 32%), since they have two additional risk factors: chronic cholestasis and female gender [8,9,15,18–23].”
BackgroundCampbell, M. S., Lichtenstein, G. R., Rhim, A. D., Pazianas, M., & Faust, T. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01075.x · Cited by 34
Patel, N., & Muñoz, S. J. (2015) · Clinical Liver Disease · doi:10.1002/cld.498 · Cited by 34
Metadata
- Authors
- Lindor, K. D., Janes, C. H., Crippin, J. S., Jorgensen, R. A., & Dickson, R. E.
- Venue
- Hepatology
- Published
- 1995-02
- Volume
- 21
- Issue
- 2
- Pages
- 389-392
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4235946641
- Cited by
- 127
- References
- 6
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.